| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 05, 2024 |
Director, PRESIDENT AND CEO
Trans History: 32
|
Director, PRESIDENT AND CEO | Form 4 | Other acquisition or disposition | -- | -- | 502 |
| Jun 03, 2024 |
CHIEF MEDICAL OFFICER
Trans History: 15
|
CHIEF MEDICAL OFFICER | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 16,000 | -- | 48,245 |
| Jun 03, 2024 |
CHIEF MEDICAL OFFICER
Trans History: 15
|
CHIEF MEDICAL OFFICER | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 75,000 | -- | 75,000 |
| Jun 03, 2024 |
GENERAL COUNSEL
Trans History: 6
|
GENERAL COUNSEL | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,500 | -- | 18,025 |
| Jun 03, 2024 |
GENERAL COUNSEL
Trans History: 6
|
GENERAL COUNSEL | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 68,000 | -- | 68,000 |
| Jun 03, 2024 |
Director, PRESIDENT AND CEO
Trans History: 32
|
Director, PRESIDENT AND CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 44,000 | -- | 121,813 |
| Jun 03, 2024 |
Director, PRESIDENT AND CEO
Trans History: 32
|
Director, PRESIDENT AND CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 204,000 | -- | 204,000 |
| Jun 03, 2024 |
Chief Financial Officer
Trans History: 4
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 16,000 | -- | 16,000 |
| Jun 03, 2024 |
Chief Financial Officer
Trans History: 4
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 75,000 | -- | 75,000 |
| Jun 03, 2024 |
CHIEF OPERATING OFFICER
Trans History: 22
|
CHIEF OPERATING OFFICER | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 16,000 | -- | 64,698 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.